MannKind stock fell 3.8 percent as analysts kept a positive view

Published on 10/04/2026 at 16:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MannKind stock closed at USD 3.80 on October 2 after a 3.80 percent decline. Second-quarter revenue rose 43 percent, while analysts kept a Moderate Buy view.

MNKD, US56400P7069, Illustration mit AI erstellt.

MannKind stock (ISIN US56400P7069) closed at USD 3.80 on Nasdaq on October 2, 2026, down 3.80 percent from the prior session. The move came as investors weighed a fast-growing revenue base against a USD 19.03 million quarterly GAAP loss and continuing development spending.

Revenue growth meets a wider loss

MannKind reported second-quarter 2026 revenue of USD 109.37 million, up 43 percent from USD 76.53 million in the same quarter of 2025, according to MarketBeat on October 2, 2026. The quarter ended June 30, 2026, with GAAP net loss of USD 19.03 million, compared with net income of USD 668,000 a year earlier.

The revenue comparison is the strongest operating signal in the latest report, but profitability moved in the opposite direction. MannKind's finance data show quarterly operating profit of negative USD 350,000 and operating cash flow of negative USD 18.37 million for Q2 2026, while cash stood at USD 52.929 million on June 30, 2026.

New pipeline option in weight management

On September 9, 2026, MannKind and Rose Pharma entered a worldwide licensing and collaboration agreement for ROSE-010 Technosphere, an investigational inhaled GLP-1 receptor agonist for weight management, according to MannKind. The company receives an equity interest, potential royalties and a board seat while supporting formulation and manufacturing through completion of a Phase 1b study.

The agreement expands the commercial story beyond Afrezza and Furoscix by applying MannKind's Technosphere inhalation platform to a new metabolic-care program. Rose Pharma retains responsibility for clinical development, regulatory strategy and commercialization, leaving MannKind with a technology and royalty-linked role in the program.

Analysts see a wide valuation gap

MarketBeat lists a Moderate Buy consensus based on 10 analysts, with seven Buy ratings, one Hold rating and two Sell ratings. Its average price target is USD 8.34, with a high of USD 13.00 and a low of USD 4.75, putting the average target 119.5 percent above the October 2 price.

H.C. Wainwright maintained a Buy rating and a USD 10.00 price target in a report dated September 21, 2026, as reported by Markets Insider on September 22, 2026. That target is 163.2 percent above the October 2 closing price, showing how sharply analyst expectations differ from the current quotation.

Stock remains below its yearly peak

MannKind traded between USD 3.71 and USD 4.01 on October 2, 2026, with volume of 4,613,896 shares. Its 52-week range is USD 2.23 to USD 6.51, leaving the stock 41.6 percent below the yearly high.

The closing price and the latest revenue figures point to a split investor debate: commercial growth is accelerating, while losses and cash use remain central to the valuation discussion. MannKind's USD 1.2 billion market capitalization places the pipeline expansion and the next earnings update alongside execution risk.